Therapeutic strategy in inflammatory myopathies (polymyositis, dermatomyositis, overlap myositis, and immune-mediated necrotizing myopathy);Prise en charge thérapeutique des polymyosites, dermatomyosites, myosites de chevauchement et myopathies nécrosantes auto-immunes

Revue de Medecine Interne

Volumn 35, Issue 7, 2014, Pages 466-471

  Tournadre, A ^a  

^a SERVICE DE RHUMATOLOGIE   (France)

Author keywords

Dermatomyositis; Immune mediated necrotizing myopathy; Inflammatory myopathy; Polymyositis; Treatment

Indexed keywords

AZATHIOPRINE; BIOLOGICAL PRODUCT; CORTICOSTEROID; IMMUNOGLOBULIN; METHOTREXATE; RITUXIMAB; GLUCOCORTICOID; IMMUNOLOGIC FACTOR; IMMUNOSUPPRESSIVE AGENT;

AUTOIMMUNE DISEASE; CLINICAL FEATURE; CONSENSUS DEVELOPMENT; DERMATOMYOSITIS; DISEASE COURSE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; DYSPHAGIA; HISTOPATHOLOGY; HUMAN; IMMUNE MEDIATED NECROTIZING MYOPATHY; IMMUNOSUPPRESSIVE TREATMENT; INCLUSION BODY MYOSITIS; INFLAMMATORY INFILTRATE; MUSCLE WEAKNESS; MYOSITIS; OUTCOME ASSESSMENT; OVERLAP MYOSITIS; POLYMYOSITIS; PREVALENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SHORT SURVEY; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT;

GLUCOCORTICOIDS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; MYOSITIS;

EID: 84902830550     PISSN: 02488663     EISSN: 17683122     Source Type: Journal    
DOI: 10.1016/j.revmed.2013.09.008     Document Type: Short Survey

References (77)

1. Bohan A., Peter J.B. Polymyositis and dermatomyositis [first of two parts]. N Engl J Med 1975, 292:344-347.
2. Hoogendijk J., Amato A.A., Lecky B.R., Choy E.H., Lundberg I.E., Rose M.R., et al. 119th ENMC international workshop: trila design in adult idiopathic inflammatory myopathies, with the exception of inclusion-body myositis. Neuromuscul Disord 2004, 14:337-345.
3. Troyanov Y., Targoff I.N., Tremblay J.L., Goulet J.R., Raymond Y., Senecal Y. Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies. Analysis of 100french canadian patients. Medicine 2005, 84:231-249.
4. Allenbach Y., Benveniste O. Acquired necrotizing myopathies. Rev Med Interne 2013, 34:363-368.
5. Tournadre A., Miossec P. A critical role for immature muscle precursors in myositis. Nat Rev Rheumatol 2013, 9:438-442.
6. Gordon P., Winer J., Hoogendijk J., Choy E. Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis. Cochrane Database Syst Rev 2012, 15:CD003643.
7. The Muscle Study Group A randomized pilot trial of etanercept in dermatomyositis. Ann Neurol 2011, 70:427-436.
8. Van de Vlekkert J., Hoogendijk J.E., De Haan R.J., Algra A., Van der Tweel I., Van der Pol W.L., et al. Oral dexamethasone pulse therapy versus daily prednisolone in sub-acute onset myositis, a randomised clinical trial. Neuromuscul Disord 2010, 20:382-389. [PUBMED: 20423755].
9. Villalba L., Hicks J.E., Adams E.M., Sherman J.B., Gourley M.F., Leff R.L., et al. Treatment of refractory myositis: a randomized crossover study of two new cytotoxic regimens. Arthritis Rheum 1998, 41:392-399.
10. Miller F.W., Leitman S.F., Cronin M.E., et al. Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis. N Engl J Med 1992, 326:1380-1384.
11. Dalakas M.C., Illa I., Dambrosia J.M., Soueidan S.A., Stein D.P., Otero C., et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993, 329:1993-2000.
12. Coyle K., Pokrovnichka A., French K., Joe G., Shrader J., Swan L., et al. Randomized, double-blind, placebo-controlled trial of infliximab in patients with polymyositis and dermatomyositis. Arthritis Rheum 2008, 58(Suppl.):2058.
13. Bunch T.W., Worthington J.W., Combs J.J., Ilstrup D.M., Engel A.G. Azathioprine with prednisone for polymyositis. A controlled, clinical trial. Ann Intern Med 1980, 92:365-369.
14. Rider L., Giannini E., Brunner H., Ruperto N., James-Newton L., Reed A., et al. International consensus on preliminary definitions of improvement in adult and juvenile myositis. Arthritis Rheum 2004, 50:2281-2290.
15. Oddis C.V., Reed A.M., Aggarwal R., Rider L.G., Ascherman D.P., Levesque M.C., et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis. Arthritis Rheum 2013, 65:314-324.
16. Sultan S., Ioannou Y., Moss K., et al. Outcome in patients with idiopathic inflammatory myositis: morbidity and mortality. Rheumatology 2002, 41:22-26.
17. Uchino M., Yamashita S., Uchino K., Hara A., Koide T., Suga T., et al. Long-term outcome of polymyositis treated with high single-dose alternate-day prednisolone therapy. Eur Neurol 2012, 68:117-121.
18. Laxer R., Stein L.D., Petty R.E. Intravenous pulse methylprednisolone treatment of juvenile dermatomyositis. Arthritis Rheum 1987, 30:328-334.
19. Seshadri R., Feldman B.M., Ilowite N., Cawkwell G., Pachman L.M. The role of aggressive corticosteroid therapy in patients with juvenile dermatomyositis: a propensity score analysis. Arthritis Rheum 2008, 59:989-995.
20. Phillips B.A., Zilko P., Garlepp M.J., Mastaglia F.L. Frequency of relapses in patients with polymyositis and dermatomyositis. Muscle Nerve 1998, 21:1668-1672.
21. Bronner I., van der Meulen M.F., de Visser M., et al. Long-term outcome in polymyositis and dermatomyositis. Ann Rheum Dis 2006, 65:1456-1461.
22. Bunch T.W. Prednisone and azathioprine for polymyositis: long-term follow-up. Arthritis Rheum 1981, 24:45-48.
23. Ramanan A.V., Campbell-Webster N., Ota S., Parker S., Tran D., Tyrrell P.N., et al. The effectiveness of treating juvenile dermatomyositis with methotrexate and aggressively tapered corticosteroids. Arthritis Rheum 2005, 52(11):3570-3578.
24. Miller J., Walsh Y., Saminaden S., Lecky B.R.F., Winer J.B. Randomised double-blind controlled trial of methotrexate and steroids compared with azathioprine and steroids in the treatment of idiopathic inflammatory myopathy. J Neurol Sci 2002, 199(Suppl 1):S53.
25. Vencovsky J., Jarosova K., Machacek S., Studynkova J., Kafkova J., Bartunkova J., et al. Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis. Scand J Rheumatol 2000, 29:95-102.
26. Gelber A.C., Nousari H.C., Wigley F.M. Mycophenolate mofetil in the treatment of severe skin manifestations of dermatomyositis: a series of 4cases. J Rheumatol 2000, 27:1542-1545.
27. Chaudhry V., Cornblath D.R., Griffin J.W., O'Brien R., Drachman D.B. Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases. Neurology 2001, 56:94-96.
28. Caramaschi P., Volpe A., Carletto A., Bambara L.M., Biasi D. Long-standing refractory polymyositis responding to mycophenolate mofetil: a case report and review of the literature. Clin Rheumatol 2007, 26:1795-1796.
29. Edge J.C., Outland J.D., Dempsey J.R., Callen J.P. Mycophenolate mofetil as an effective corticosteroid-sparing therapy for recalcitrant dermatomyositis. Arch Dermatol 2006, 142:65-69.
30. Majithia V., Harisdangkul V. Mycophenolate mofetil (CellCept): an alternative therapy for autoimmune inflammatory myopathy. Rheumatology (Oxford) 2005, 44:386-389.
31. Morganroth P.A., Kreider M.E., Werth V.P. Mycophenolate mofetil for interstitial lung disease in dermatomyositis. Arthritis Care Res (Hoboken) 2010, 62:1496-1501.
32. Pisoni C.N., Cuadrado M.J., Khamashta M.A., Hughes G.R., D'Cruz D.P. Mycophenolate mofetil treatment in resistant myositis. Rheumatology (Oxford) 2007, 46:516-518.
33. Rowin J., Amato A.A., Deisher N., Cursio J., Meriggioli M.N. Mycophenolate mofetil in dermatomyositis: is it safe?. Neurology 2006, 66:1245-1247.
34. Saketkoo L.A., Espinoza L.R. Experience of mycophenolate mofetil in 10patients with autoimmune-related interstitial lung disease demonstrates promising effects. Am J Med Sci 2009, 337:329-335.
35. Schneider C., Gold R., Schafers M., Toyka K.V. Mycophenolate mofetil in the therapy of polymyositis associated with a polyautoimmune syndrome. Muscle Nerve 2002, 25:286-288.
36. Boswell J.S., Costner M.I. Leflunomide as adjuvant treatment of dermatomyositis. J Am Acad Dermatol 2008, 58:403-406.
37. Lange U., Piegsa M., Muller-Ladner U., Strunk J. Anti-Jo-1antibody positive polymyositis - successful therapy with leflunomide. Autoimmunity 2006, 39:261-264.
38. Sangle V.S., Sangle S.R., D'Cruz D.P. Leflunomide as a remission-maintaining therapy in difficult-to-treat dermatomyositis. Ann Rheum Dis 2008, 67:723.
39. Yamasaki Y., Yamada H., Yamasaki M., Ohkubo M., Azuma K., Matsuoka S., et al. Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis/dermatomyositis. Rheumatology (Oxford) 2007, 46:124-130.
40. Tournadre A., Porcherot M., Chérin P., Marie I., Hachulla E., Miossec P. Th1and Th17balance in inflammatory myopathies: interaction with dendritic cells and possible link with response to high-dose immunoglobulins. Cytokine 2009, 46:297-301.
41. Kampylafka E.I., Kosmidis M.L., Panagiotakos D.B., Dalakas M.C., Moutsopoulos H.M., Tzioufas A.G. The effect of intravenous immunoglobulin [IVIG] treatment on patients with dermatomyositis: a 4-year follow-up study. Clin Exp Rheumatol 2012, 30:397-401.
42. Cherin P., Pelletier S., Teixeira A., Laforet P., Genereau T., Simon A., et al. Results and long-term follow-up of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients. Arthritis Rheum 2002, 46:467-474.
43. Danieli M.G., Malcangi G., Palmieri C., Logullo F., Salvi A., Piani M., et al. Cyclosporin A and intravenous immunoglobulins treatment in polymyositis/dermatomyositis. Ann Rheumatic Dis 2002, 61:37-41.
44. Marie I., Menard J.F., Hatron P.Y., Hachulla E., Mouthon L., Tiev K., et al. Intravenous immunoglobulins for steroid-refractory esophageal involvement related to polymyositis and dermatomyositis: a series of 73patients. Arthritis Care Res (Hoboken) 2010, 62:1748-1755.
45. Werner J.L., Christopher-Stine L., Ghazarian S.R., Pak K.S., Kus J.E., Daya N.R., et al. Antibody levels correlate with creatine kinase levels and strenght in anti-3-hydroxy-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Arthritis Rheum 2012, 64:4087-4093.
46. Christopher-Stine L., Casciola-Rosen L., Hong G., Chung T., Corse A.M., Mammen A.L. A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy. Arthritis Rheum 2010, 62:2757-2766.
47. Diot E., Carmier D., Marquette D., Marchand-Adam S., Diot P., Lesire V. IV immunoglobulin might be considered as a first-line treatment of severe interstitial lung disease associated with polymyositis. Chest 2011, 140:562-563.
48. Bakewell J.C., Raghu G. Polmyositis associated with severe interstitial lung disease: remission after three doses of IV immunoglobulin. Chest 2011, 139:441-443.
49. Danieli M.G., Pettinari L., Moretti R., Logullo F., Gabrielli A. Subcutaneous immunoglobulin in polymyositis and dermatomyositis: a novel application. Autoimmun Rev 2011, 10:144-149.
50. Chevrel G., Granet C., Miossec P. Contribution of tumour necrosis factor alpha and interleukin [IL] 1beta to IL6production, NF-kappaB nuclear translocation, and class I MHC expression in muscle cells: in vitro regulation with specific cytokine inhibitors. Ann Rheum Dis 2005, 64:1257-1262.
51. Hengstman G.J., De Bleecker J.L., Feist E., Vissing J., Denton C.P., Manoussakis M.N., et al. Open-label trial of anti-TNF-alpha in dermato- and polymyositis treated concomitantly with methotrexate. Eur Neurol 2008, 59:159-163.
52. Efthimiou P., Schwartzman S., Kagen L.J. Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients. Ann Rheum Dis 2006, 65:1233-1236.
53. Iannone F., Scioscia C., Falappone P.C., Covelli M., Lapadula G. Use of etanercept in the treatment of dermatomyositis: a case series. J Rheumatol 2006, 33:1802-1804.
54. Dastmalchi M., Grundtman C., Alexanderson H., Mavragani C.P., Einarsdottir H., Helmers S.B., et al. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis 2008, 67:1670-1677.
55. Eloranta M.L., Barbasso Helmers S., Ulfgren A.K., Rönnblom L., Alm G.V., Lundberg I.E. A possible mechanism for endogenous activation of the type I interferon system in myositis patients with anti-Jo-1or anti-Ro 52/anti-Ro 60autoantibodies. Arthritis Rheum 2007, 56:3112-3124.
56. Dorph C., Dastmalchi M., Alexanderson H., Ottosson C., Lindroos E.I.N., et al. Anakinra with refractory idiopathic inflammatory myopathies. Arthritis Rheum 2009, 60(Suppl. 10):589.
57. Levine T.D. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum 2005, 52:601-607.
58. Lambotte O., Kotb R., Maigne G., Blanc F.X., Goujard C., Delfraissy J.F. Efficacy of rituximab in refractory polymyositis. J Rheumatol 2005, 32:1369-1370.
59. Chiappetta N., Steier J., Gruber B. Rituximab in the treatment of refractory dermatomyositis. J Clin Rheumatol 2005, 11:264-266.
60. Noss E.H., Hausner-Sypek D.L., Weinblatt M.E. Rituximab as therapy for refractory polymyositis and dermatomyositis. J Rheumatol 2006, 33:1021-1026.
61. Brulhart L., Waldburger J.M., Gabay C. Rituximab in the treatment of antisynthetase syndrome. Ann Rheum Dis 2006, 65:974-975.
62. Chung L., Genovese M.C., Fiorentino D.F. A pilot trial of rituximab in the treatment of patients with dermatomyositis. Arch Dermatol 2007, 143:763-767.
63. Mok C.C., Ho L.Y., To C.H. Rituximab for refractory polymyositis: an open-label prospective study. J Rheumatol 2007, 34:1864-1868.
64. Tournadre A., Amarger S., Joly P., et al. Polymyositis and pemphigus vulgaris in a patient: successful treatment with rituximab. Joint Bone Spine 2008, 75:728-729.
65. Couderc M., Gottenberg J.E., Mariette X., Hachulla E., Sibilia J., Fain O., et al. Efficay and safety of rituximab in the treatment of refractory inflammatory myopathies in adults: results from the AIR registry. Rheumatology (Oxford) 2011, 50:2283-2289.
66. Sem M., Molberg O., Lund M.B., Gran J.T. Rituximab treatment of the anti-synthetase syndrome: a retrospective case series. Rheumatology (Oxford) 2009, 48:968-971.
67. Frikha F., Rigolet A., Behin A., Fautrel B., Herson S., Benveniste O. Efficacy of rituximab in refractory and relapsing myositis with anti-JO1antibodies: a report of two cases. Rheumatology (Oxford) 2009, 48:1166-1168.
68. Arlet J.B., Dimitri D., Pagnoux C., et al. Marked efficacy of a therapeutic strategy associating prednisone and plasma exchange followed by rituximab in two patients with refractory myopathy associated with antibodies to the signal recognition particle (SRP). Neuromuscul Disord 2006, 16:334-336.
69. Valiyil R., Casciola-Rosen L., Hong G., Mammen A.L., Christopher-Stine L. Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series. Arthritis Care Res (Hoboken) 2010, 62:1328-1334.
70. Narazaki M., Hagihara K., Shima Y., Ogata A., Kishimoto T., Tanaka T. Therapeutic effect of tocilizumab on two patients with polymyositis. Rheumatology (Oxford) 2011, 50:1344-1346.
71. Dieval C., Ribeiro E., Mercié P., Blanco P., Duffau P., Longy-Boursier M. Antisynthetase syndrome: a retrospective study of 14patients. Rev Med Interne 2012, 33:76-79.
72. Fathi M., Vikgren J., Boijsen M., et al. Interstitial lung disease in polymyositis and dermatomyositis: longitudinal evaluation by pulmonary function and radiology. Arthritis Rheum 2008, 59:677-685.
73. Marie I., Josse S., Hatron P.Y., Dominique S., Hachulla E., Janvresse A., et al. Interstitial lung disease in anti-JO1patients with antisynthetase syndrome. Arthritis Care Res (Hoboken) 2013, 65:800-808.
74. Tournadre A., Soubrier M. Le rhumatologue face à une myopathie cortisonique. Rev Rhum 2008, 75:157-161.
75. de Salles Painelli V., Gualano B., Artioli G.G., de Sa Pinto A.L., Bonfa E., Lancha Junior A.H., et al. The possible role of physical exercise on the treatment of idiopathic inflammatory myopathies. Autoimmun Rev 2009, 8:355-359.
76. Alexanderson H., Dastmalchi M., Esbjornsson-Liljedahl M., Opava C.H., Lundberg I.E. Benefits of intensive resistance training in patients with chronic polymyositis or dermatomyositis. Arthritis Rheum 2007, 57:768-777.
77. Chung Y.L., Alexanderson H., Pipitone N., Morrison C., Dastmalchi M., Stahl-Hallengren C., et al. Creatine supplements in patients with idiopathic inflammatory myopathies who are clinically weak after conventional pharmacologic treatment: six-month, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2007, 57:694-702.